Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2001- : London : BioMed Central Ltd.
      Original Publication: London : Current Science Ltd., c2000-
    • الموضوع:
      Disease Progression*; Albuterol/*analogs & derivatives ; Androstadienes/*administration & dosage ; Bronchodilator Agents/*administration & dosage ; Pulmonary Disease, Chronic Obstructive/*diagnosis ; Pulmonary Disease, Chronic Obstructive/*drug therapy; Administration, Inhalation ; Aged ; Albuterol/administration & dosage ; Double-Blind Method ; Drug Combinations ; Female ; Fluticasone-Salmeterol Drug Combination ; Humans ; Male ; Middle Aged ; Salmeterol Xinafoate
    • نبذة مختصرة :
      Background: Inhaled long-acting beta2 agonists used alone and in combination with an inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD. However, the relative efficacy of these agents in preventing recurrent exacerbations in those recovering from an initial episode is not known. This study compared the rate of COPD exacerbations over the 26 weeks after an initial exacerbation in patients receiving the combination of fluticasone propionate and salmeterol (FP/SAL) or SAL alone.
      Methods: Patients (n = 639) aged ≥40 years were randomized to either twice-daily inhaled FP/SAL 250/50 μg or SAL 50 μg. Primary, and secondary, endpoints were rates of recurrent severe, and moderate/severe, exacerbations of COPD. Lung function, health outcomes and levels of biomarkers of systemic inflammation were also assessed.
      Results: There was no statistically significant treatment difference in rates of recurrent severe exacerbations (treatment ratio 0.92 [95% CI: 0.58, 1.45]) and moderate/severe exacerbations (0.82 [0.64, 1.06]) between FP/SAL and SAL in the intent-to-treat population. Pre-dose morning FEV1 change from baseline was greater (0.10 L [0.04, 0.16]) with FP/SAL than SAL. No treatment difference was seen for other endpoints including patient-reported health outcomes and biomarker levels for the full cohort.
      Conclusions: No significant treatment difference between FP/SAL and SAL was seen in COPD exacerbation recurrence for the complete cohort. Treatment benefit with FP/SAL over SAL (treatment ratio 0.68 [0.47, 0.97]) was seen in patients having FEV1 ≥ 30% and prior exposure to ICS. No unexpected safety issues were identified with either treatment. Patients with the most severe COPD may be more refractory to treatment.
      Trial Registration: ClinicalTrials.gov (identifier NCT01110200). This study was funded by GlaxoSmithKline (study number ADC113874).
    • References:
      Lancet. 2007 Sep 1;370(9589):786-96. (PMID: 17765528)
      Am J Respir Crit Care Med. 2002 Nov 15;166(10):1358-63. (PMID: 12406823)
      Lung. 2011 Aug;189(4):261-8. (PMID: 21678045)
      Health Qual Life Outcomes. 2009 Jul 22;7:69. (PMID: 19624834)
      Am J Respir Crit Care Med. 2001 Nov 1;164(9):1618-23. (PMID: 11719299)
      Eur Respir Rev. 2010 Jun;19(116):113-8. (PMID: 20956179)
      Chest. 2003 Sep;124(3):834-43. (PMID: 12970006)
      Thorax. 2002 Oct;57(10):847-52. (PMID: 12324669)
      Thorax. 2011 May;66(5):363-4. (PMID: 21248321)
      Eur Respir J. 2007 Mar;29(3):527-34. (PMID: 17107990)
      Eur Respir J. 2012 Dec;40(6):1318-9. (PMID: 23204018)
      Respir Res. 2011 Nov 04;12:146. (PMID: 22054035)
      N Engl J Med. 2009 Apr 2;360(14):1418-28. (PMID: 19339721)
      Chest. 2008 Feb;133(2):350-7. (PMID: 18198263)
      N Engl J Med. 2010 Sep 16;363(12):1128-38. (PMID: 20843247)
      Chest. 2012 Jan;141(1):81-86. (PMID: 21799028)
      N Engl J Med. 2011 Sep 29;365(13):1184-92. (PMID: 21991892)
      Respir Med. 2008 Aug;102(8):1099-108. (PMID: 18614347)
      Am J Respir Crit Care Med. 2008 Jan 1;177(1):19-26. (PMID: 17916806)
      Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55. (PMID: 22447964)
      Eur Respir J. 2009 Aug;34(2):507-12. (PMID: 19648525)
      Thorax. 2005 Jun;60(6):480-7. (PMID: 15923248)
      Chest. 2009 Oct;136(4):1029-1038. (PMID: 19633090)
      QJM. 2009 Mar;102(3):193-202. (PMID: 19147657)
      Thorax. 2012 Nov;67(11):957-63. (PMID: 22684094)
      Am J Respir Crit Care Med. 2009 Mar 1;179(5):369-74. (PMID: 19074596)
      N Engl J Med. 2007 Feb 22;356(8):775-89. (PMID: 17314337)
      Am J Respir Crit Care Med. 2000 May;161(5):1608-13. (PMID: 10806163)
      Am J Respir Crit Care Med. 2011 Feb 1;183(3):323-9. (PMID: 20813886)
      Eur Respir J. 2004 May;23(5):698-702. (PMID: 15176682)
      Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 2):S77-121. (PMID: 7582322)
      Chest. 2012 Feb;141(2):396-405. (PMID: 21835899)
      Eur Respir J. 2009 Jul;34(1):95-102. (PMID: 19164344)
      COPD. 2009 Oct;6(5):320-9. (PMID: 19863361)
      Eur Respir J. 2012 Jan;39(1):38-45. (PMID: 21737561)
      Am J Respir Med. 2003;2(1):67-74. (PMID: 14720023)
      COPD. 2005 Mar;2(1):81-9. (PMID: 17136967)
      Ann Intern Med. 2007 Apr 17;146(8):545-55. (PMID: 17310045)
    • Molecular Sequence:
      ClinicalTrials.gov NCT01110200
    • الرقم المعرف:
      0 (Androstadienes)
      0 (Bronchodilator Agents)
      0 (Drug Combinations)
      0 (Fluticasone-Salmeterol Drug Combination)
      6EW8Q962A5 (Salmeterol Xinafoate)
      QF8SVZ843E (Albuterol)
    • الموضوع:
      Date Created: 20140925 Date Completed: 20150417 Latest Revision: 20240508
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC4176847
    • الرقم المعرف:
      10.1186/s12931-014-0105-2
    • الرقم المعرف:
      25248764